ClinicalTrials.gg

Program

RBD4059

A development code.

Its studies are mostly in Coronary Artery Disease, led by Suzhou Ribo Life Science.

Furthest: phase 2, since Nov 4, 20243 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Ribo Life Science31 open or runningphase 2since Nov 4, 2024Nov 21, 2022Aug 2027phase 1 · NCT07930767

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05653037 · 32 enrolled · Australia
  2. Nov 4, 2024Phase 2 study in Stable Coronary Artery Disease CADNCT06717074 · 30 enrolled · Sweden
  3. Nov 5, 2026Phase 1 study in HealthyNCT07930767 · 30 planned

Ahead

  1. Aug 2027Primary completion: phase 1 study in HealthyNCT07930767

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07930767Healthy1Not yet recruitingAug 202730
NCT06717074Stable Coronary Artery Disease CAD · Sweden2CompletedApr 29, 202630
NCT05653037Healthy Volunteers · Australia1CompletedOct 1, 202432

How it is read

Names in the registry

  • “RBD4059”, 3 entries

Codes read as this program: RBD4059.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.